2-[4-[4-(Aminomethyl)-1-Oxo-2H-Phthalazin-6-Yl]-2-Methylpyrazol-3-Yl]-4-Chloro-6-Cyclopropyloxy-3-Fluorobenzonitrile

3 trials 2 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

2 Recruiting

1 Completed trials

1 Sponsors

17 Countries

Phase II/III

Phase II

Phase II/III: 2 Phase II: 1

Indications tested

Non-small cell lung cancer metastatic 1 Non-small cell lung cancer recurrent 1

Sponsors using this IMP

Bristol-Myers Squibb Services Unlimited Company 3

All trials

3 total

A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 Phase II/III 15 countries Bristol-Myers Squibb Services Unlimited Company
A Study of Navlimetostat (BMS986504) in Participants with Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer with Homozygous MTAP… Recruiting

2024-519814-29-00 Phase II 7 countries Bristol-Myers Squibb Services Unlimited Company
A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou… Ended

2025-522598-12-00 Phase II/III 15 countries Bristol-Myers Squibb Services Unlimited Company

Showing 1–3 of 3 trials

← All drugs A–Z